Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Astegolimab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ZARNIE
- Sponsors Genentech
- 27 Aug 2022 Status changed from active, no longer recruiting to discontinued, according to the results published in the Journal of Allergy and Clinical Immunology.
- 27 Aug 2022 Primary endpoint (Percent Change of Total Eczema Area and Severity Index (EASI) Score) has not been met, according to Results published in the Journal of Allergy and Clinical Immunology.
- 27 Aug 2022 Results assessing the efficacy, safety, and pharmacokinetics of astegolimab in patients with atopic dermatitis published in the Journal of Allergy and Clinical Immunology